MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Ovid therapeutics Inc

Fechado

SetorSaúde

0.33 3.12

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.32

Máximo

0.33

Indicadores-chave

By Trading Economics

Rendimento

-982K

-10M

Vendas

54K

130K

EPS

-0.14

Margem de lucro

-7,873.077

Funcionários

23

EBITDA

-1.8M

-12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+732.35% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.4M

23M

Abertura anterior

-2.79

Fecho anterior

0.33

Sentimento de Notícias

By Acuity

50%

50%

115 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jul. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 15:57 UTC

Conversa de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 de jul. de 2025, 15:49 UTC

Conversa de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Received All Required Authorizations

4 de jul. de 2025, 15:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Agreement Was Announced on Dec. 19

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 de jul. de 2025, 15:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 de jul. de 2025, 14:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 de jul. de 2025, 13:53 UTC

Conversa de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de jul. de 2025, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 de jul. de 2025, 12:30 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 de jul. de 2025, 12:15 UTC

Conversa de Mercado

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 de jul. de 2025, 12:13 UTC

Conversa de Mercado

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 de jul. de 2025, 12:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

732.35% parte superior

Previsão para 12 meses

Média 2.83 USD  732.35%

Máximo 4 USD

Mínimo 1.5 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

115 / 375 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.